Cellectis SA (CLLS)
$1.85 -$0.07 (-3.68%) 4:38 PM 12/12/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$200.19M -
Day's Range
$1.82 - $1.93 -
Volume
57,660 -
52 Week Low / High
$1.70 - $3.77 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
CLLS's Dividend
Hypothetical 10k Investment Jan 1, 2020
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
Analyists Ranking
- 3
- Strong Buy
- 2
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong Sell
- $7.50
- Target Price
Company News
-
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB) — Jan 16th, 2024
Cellectis Inc. NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it h...
|
Portfolio
$5,000/year
Goal: $10,000/year
Comprised of 1 portfolios
$